November 6, 2017—BTG International advised that the Centers for Medicare & Medicaid Services published the final fee schedule for new category I CPT codes for the company's Varithena procedures. The codes become effective on January 1, 2018.
The fee schedule details payments for conducting Varithena treatments in the physician office setting of $1,624.30 for a single vein and $1,697.02 for multiple veins. The new CPT codes define Medicare payment rates and enable automatic and electronic processing of claims. This will provide physicians in the United States with additional predictability of payments and streamlining of the reimbursement process, stated BTG.
advertisement
Sponsored by EKOS Corporation
Related Articles
Ask the Experts: Which Forces Most Drive Platform Adoption in Superficial Venous Care?
A panel discusses how they navigate the technologies available for treating superficial venous disease and the factors that influence widespread adoption.
With Julianne Stoughton, MD, FACS; Thomas Proebstle, MD; Neil Khilnani, MD, FSIR, FACPh; and Steve Elias, MD, FACS, FACPh
Top 5 Articles From October 2017
Ensuring a Good Death: Pain Management and Palliative Procedures in the Oncology Patient
Examining the role of the interventional radiologist in providing end-of-life care.
By Joshua D. Kuban, MD; and Alda Tam, MD
Treating Peripheral Artery Disease in the Popliteal Artery: DA + DCB Versus DCB Alone
By Konstantinos Stavroulakis, MD
The Interventional Oncology Clinic: Introduction to the IO Clinical Care Model
Assessing interventional oncology patients in an outpatient clinic setting is essential for providing longitudinal and optimal care.
By Eric A. Wang, MD; Mendi D. Mullis, MBA; and Megan E. Kanable, MHA
Interventional Oncology: Precision in Practice
By Ripal Gandhi, MD, FSVM; and David M. Liu, MD, FRCPC, FSIR
Locoregional Management Pathways for Liver Cancer
A practical approach to treating tumors in the liver caused by primary liver cancer, colorectal cancer, and neuroendocrine tumors.
By Martin Edwards, MD; and Siddharth A. Padia, MD
Top 5 from CIToday's Current Issue
Trends in United States TAVR Practice
An update on where TAVR is going as the technology matures in the United States.
By John C. Messenger, MD
Worldwide Trends in TAVR
By Ted E. Feldman, MD, MSCAI, FACC, FESC; and Bernard Prendergast, BMedSci, BM BS, MRCP, DM, FRCP, FESC
Current Status and Expectations for Low-Risk TAVI Trials
An expert opinion on how current clinical trials will impact the future of TAVI procedures in low-risk patients.
With Marc Dweck, MD, PhD
Risk Assessment for Transcatheter Aortic Valve Replacement
Understanding STS score, EuroSCORE, and frailty indices.
By Troels Højsgaard Jørgensen, MD; and Lars Søndergaard, MD, DMSc
Trends in European TAVI Practice
Current application of TAVI in Europe.
